ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2423

Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
Abstract Number: 2425

Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes
Abstract Number: 2426

Physical Activity Patterns and Health-Related Quality of Life in Middle-Aged and Older Adults with Systemic Lupus Erythematosus
Abstract Number: 2427

Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease
Abstract Number: 2428

Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes
Abstract Number: 2429

mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
Abstract Number: 2430

Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
Abstract Number: 2431

Bone marrow- activity on 18F-FDG PET/CT as a Predictor of Hematologic Manifestations in Systemic Lupus Erythematosus
Abstract Number: 2432

Duffy Null Genotype and Autoantibodies Synergistically Contribute to Severe Leukopenia in Systemic Lupus Erythematosus
Abstract Number: 2433

The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation
Abstract Number: 2434

Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Abstract Number: 2435

Relevant Symptoms and Signs of Active Discoid and/or Subacute Cutaneous Lupus Erythematosus Among Participants in a Phase 2 Clinical Trial: Patient-Embedded Qualitative Interviews
Abstract Number: 2436

Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE
Abstract Number: 2437

Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
Abstract Number: 2438

SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].